GNLX Stock Summary and Trading Ideas (Genelux | NASDAQ:GNLX)

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Genelux trades on the NASDAQ stock market under the symbol GNLX.

As of September 24, 2026, GNLX stock price declined to $2.43 with 150,596 million shares trading.

GNLX has a beta of 1.53, meaning it tends to be more sensitive to market movements. GNLX has a correlation of 0.05 to the broad based SPY ETF.

GNLX has a market cap of $109.95 million. This is considered a Micro Cap stock.

In the last 3 years, GNLX traded as high as $28.36 and as low as $1.60.

The top ETF exchange traded funds that GNLX belongs to (by Net Assets): VTI, VXF.

GNLX has underperformed the market in the last year with a price return of -44.0% while the SPY ETF gained +16.8%. GNLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.8% and -3.6%, respectively, while the SPY returned +4.8% and +0.9%, respectively.

GNLX support price is $2.41 and resistance is $2.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNLX shares will trade within this expected range on the day.